- Home
- MYGN vs SYBT Comparison
MYGN vs SYBT Comparison
Compare MYGN & SYBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- SYBT
- Stock Information
- Founded
- MYGN 1991
- SYBT 1904
- Country
- MYGN United States
- SYBT United States
- Employees
- MYGN N/A
- SYBT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SYBT Major Banks
- Sector
- MYGN Health Care
- SYBT Finance
- Exchange
- MYGN Nasdaq
- SYBT Nasdaq
- Market Cap
- MYGN 642.0M
- SYBT 2.3B
- IPO Year
- MYGN 1995
- SYBT N/A
- Fundamental
- Price
- MYGN $7.50
- SYBT $74.81
- Analyst Decision
- MYGN Hold
- SYBT Hold
- Analyst Count
- MYGN 13
- SYBT 3
- Target Price
- MYGN $13.50
- SYBT $83.67
- AVG Volume (30 Days)
- MYGN 1.4M
- SYBT 86.5K
- Earning Date
- MYGN 11-06-2025
- SYBT 10-22-2025
- Dividend Yield
- MYGN N/A
- SYBT 1.63%
- EPS Growth
- MYGN N/A
- SYBT 22.18
- EPS
- MYGN N/A
- SYBT 4.35
- Revenue
- MYGN $832,900,000.00
- SYBT $364,546,000.00
- Revenue This Year
- MYGN $0.17
- SYBT $16.83
- Revenue Next Year
- MYGN $6.19
- SYBT $5.12
- P/E Ratio
- MYGN N/A
- SYBT $17.45
- Revenue Growth
- MYGN 3.83
- SYBT 11.32
- 52 Week Low
- MYGN $3.76
- SYBT $57.12
- 52 Week High
- MYGN $29.30
- SYBT $83.83
- Technical
- Relative Strength Index (RSI)
- MYGN 68.28
- SYBT 50.67
- Support Level
- MYGN $7.13
- SYBT N/A
- Resistance Level
- MYGN $7.80
- SYBT $77.82
- Average True Range (ATR)
- MYGN 0.43
- SYBT 1.60
- MACD
- MYGN 0.06
- SYBT -3.40
- Stochastic Oscillator
- MYGN 85.15
- SYBT 89.24
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.